Cagrilintide Interactions: Alcohol, Caffeine, Food & Other Compounds

This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical question. It summarises what the published literature reports about cagrilintide in combination with other substances, and — just as importantly — where the literature is silent.

The Short Version: One Studied Combination, Many Unstudied Ones

Cagrilintide is a long-acting amylin analogue developed through acylation chemistry that extended its half-life sufficiently for once-weekly administration, as described in the medicinal chemistry paper documenting its development (PMID 34288673). A 2024 review characterised it as a long-acting amylin analogue investigated for obesity (PMID 36883831).

When readers ask about "cagrilintide interactions", the honest structure of the evidence is lopsided. One combination has been studied extensively in randomised controlled trials: cagrilintide together with semaglutide, reported in adults with overweight or obesity (PMID 40544433) and in adults with overweight or obesity and type 2 diabetes (PMID 40544432). Alcohol, caffeine, meal timing, fasting protocols and most other compounds have not been the subject of dedicated cagrilintide interaction studies in the verified literature reviewed here.

Cagrilintide and Semaglutide: The Combination That Was Actually Trialled

The most thoroughly documented cagrilintide combination is with the GLP-1 receptor agonist semaglutide. The 2025 New England Journal of Medicine report on coadministered cagrilintide and semaglutide in adults with overweight or obesity described the randomised evaluation of the two agents given together (PMID 40544433). A companion 2025 report examined the same coadministration in adults with overweight or obesity and type 2 diabetes (PMID 40544432).

A phase 3 double-blind randomised controlled study, REIMAGINE 2, compared cagrilintide–semaglutide against semaglutide alone and against cagrilintide alone in people with type 2 diabetes (PMID 42251859). That three-arm design is the closest thing in the literature to a formal interaction study, because it separated the combination from each single agent rather than only testing the pair.

Reviews have placed this pairing in context. A 2026 endocrine review discussed novel GLP-1-based medications for type 2 diabetes and obesity, including amylin-based combination approaches (PMID 41054801), and a review of incretin-based therapies for obesity-related diseases covered the broader class within which these combinations sit (PMID 40604322). A 2025 weight-management review similarly situated cagrilintide among pharmacological options for obesity (PMID 40865172).

The mechanistic rationale researchers describe (labelled as reasoning, not as trial data): amylin and GLP-1 act through distinct receptor systems that both influence satiety signalling. A 2024 review of amylin as a neuroendocrine hormone in "diabesity" described amylin's role alongside other metabolic hormones (PMID 38338796), and a 2024 expert review of amylin analogues for obesity without diabetes discussed the present and future of the class (PMID 39317404). Researchers reason that separate signalling pathways may be engaged concurrently — but whether any given clinical outcome reflects addition, synergy or neither is a question the trials themselves, not the mechanism, had to answer.

Cagrilintide and Alcohol: What the Literature Shows

No dedicated interaction study exists in the verified literature reviewed here. None of the cagrilintide trials or amylin reviews cited on this page examined alcohol co-exposure as a study variable, reported blood alcohol pharmacokinetics under cagrilintide, or stratified outcomes by alcohol intake. Any statement that alcohol "is fine" or "is not fine" with cagrilintide would not be drawn from published cagrilintide research.

The mechanistic reasoning researchers use (clearly labelled as reasoning, not evidence): amylin analogues are described in the class literature as slowing gastric emptying and acting on central satiety pathways (PMID 38338796). Because gastric emptying rate influences how quickly substances taken orally reach the small intestine, pharmacologists reason that any agent slowing gastric transit could in principle alter the time-course of oral absorption of co-ingested substances. That is a general pharmacological principle about gastric emptying, not a measured cagrilintide–alcohol finding, and it has not been quantified for cagrilintide in the papers cited here.

A second thread of reasoning concerns overlapping symptoms. The cagrilintide–semaglutide trials reported gastrointestinal adverse events as the predominant tolerability issue in adults with overweight or obesity (PMID 40544433). Researchers note that symptoms attributable to a study drug and symptoms attributable to other exposures can be difficult to disentangle when both produce nausea — which is a reason trials often control such variables, not a finding about their combination.

Cagrilintide and Caffeine: What the Literature Shows

No published cagrilintide–caffeine interaction study appears in the verified literature reviewed here. The trials of coadministered cagrilintide and semaglutide did not report caffeine as an exposure variable (PMID 40544432), and the reviews of amylin analogues for obesity did not address caffeine (PMID 39317404).

Mechanistic reasoning, labelled as such: cagrilintide was engineered as an acylated peptide with a long plasma half-life supporting weekly administration (PMID 34288673). Peptides of this design are generally described as cleared by proteolytic degradation rather than by the hepatic cytochrome P450 enzymes that handle caffeine metabolism, so researchers reason that a direct metabolic-enzyme interaction would be an unusual mechanism to expect. This is inference from peptide pharmacology, not from a caffeine co-administration experiment, and no such experiment is cited here.

Food, Meal Timing and Fasting

Cagrilintide is a subcutaneously administered peptide, so the question of "taking it with food" does not arise in the way it does for oral drugs. What the literature does address is food intake as an outcome: amylin analogues are discussed in the class literature in terms of satiety and food intake regulation (PMID 38338796), and a 2022 pharmacology handbook chapter on drugs for treating obesity placed amylin-based agents within the appetite-acting drug classes (PMID 34783910).

No trial cited here randomised participants to fasting schedules, ketogenic diets, time-restricted eating or specific meal patterns while receiving cagrilintide. The phase 3 REIMAGINE 2 study compared cagrilintide–semaglutide with each monotherapy in people with type 2 diabetes (PMID 42251859); dietary protocol comparison was not its design question. Claims that a particular eating pattern amplifies or blunts cagrilintide's effects are therefore not supported by the studies listed on this page.

Other Amylin-Acting Compounds

Interest in combining or comparing amylin receptor agonists has grown as more enter development. A 2025 paper described eloralintide (LY3841136), a novel amylin receptor agonist for obesity, from discovery through clinical proof of concept (PMID 41109426). That paper documented a separate molecule's development programme; it did not report co-administration of eloralintide with cagrilintide, and no head-to-head or combination study of two amylin analogues is cited on this page.

Researchers reason that two agonists at the same receptor family would be expected to produce overlapping rather than complementary pharmacology — which is one stated rationale for pairing amylin agents with mechanistically different partners such as GLP-1 receptor agonists (PMID 41054801). Again, this is design reasoning described in reviews, not the output of a combination trial.

What the Evidence Base Looks Like at a Glance

Tolerability in Combination Trials: What Studies Report

Because adverse events are where combination questions usually land, it is worth stating what the trials themselves reported. The 2025 study of coadministered cagrilintide and semaglutide in adults with overweight or obesity reported gastrointestinal adverse events as the most common category among treated participants (PMID 40544433). The parallel 2025 study in adults with overweight or obesity and type 2 diabetes likewise reported gastrointestinal events as the predominant adverse-event type (PMID 40544432). The phase 3 REIMAGINE 2 study reported safety outcomes for cagrilintide–semaglutide alongside each monotherapy arm in people with type 2 diabetes (PMID 42251859).

Reviews of the class have described gastrointestinal tolerability as a recurring theme for amylin analogues in obesity (PMID 39317404) and for cagrilintide specifically (PMID 36883831). None of these reports attributed adverse events to alcohol, caffeine or dietary co-exposures, because those variables were not studied.

How to Read "No Interaction Study Exists"

An absence of interaction data is not the same as evidence of no interaction, and it is not evidence of an interaction either. It means the question has not been asked in the published trials cited here. Cagrilintide's clinical programme, as reflected in the 2025 and 2026 reports, concentrated on efficacy and safety of the compound and of its combination with semaglutide (PMID 40544433, PMID 42251859), and reviews to date have summarised that programme rather than lifestyle co-exposures (PMID 40865172).

Readers looking for background on the compound itself may find the overview at /learn/cagrilintide/ useful. This page is for educational purposes only and is not medical advice; consult a licensed physician about anything involving your health or medications.

References

• Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity (The New England Journal of Medicine, 2025)
• Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes (The New England Journal of Medicine, 2025)
• Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study (The Lancet Diabetes & Endocrinology, 2026)
• Cagrilintide: A Long-Acting Amylin Analog for the Treatment of Obesity (Cardiology in Review, 2024)
• Amylin, Another Important Neuroendocrine Hormone for the Treatment of Diabesity (International Journal of Molecular Sciences, 2024)
• Amylin analogs for the treatment of obesity without diabetes: present and future (Expert Review of Clinical Pharmacology, 2024)
• Development of Cagrilintide, a Long-Acting Amylin Analogue (Journal of Medicinal Chemistry, 2021)
• Drugs for Treating Obesity (Handbook of Experimental Pharmacology, 2022)
• Weight management treatment in obesity (Medicina Clinica, 2025)
• Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept (Molecular Metabolism, 2025)
• Novel GLP-1-based Medications for Type 2 Diabetes and Obesity (Endocrine Reviews, 2026)
• Incretin-based therapies for the treatment of obesity-related diseases (npj Metabolic Health and Disease, 2024)